RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sinphar Pharmaceutical Co Stock

Sinphar Pharmaceutical Co P/S 2024

Sinphar Pharmaceutical Co P/S

1.79

Ticker

1734.TW

ISIN

TW0001734002

As of Sep 29, 2024, Sinphar Pharmaceutical Co's P/S ratio stood at 1.79, a 16.99% change from the 1.53 P/S ratio recorded in the previous year.

The Sinphar Pharmaceutical Co P/S history

Sinphar Pharmaceutical Co Aktienanalyse

What does Sinphar Pharmaceutical Co do?

Sinphar Pharmaceutical Co Ltd is a Taiwanese company specializing in the pharmaceutical industry, founded in 1970. It is a leading manufacturer of pharmaceuticals and specializes in the production of generics and branded drugs. The company is headquartered in Taipei, Taiwan and has become an important player in the global pharmaceutical market in recent years. It has several divisions specializing in the production of drugs, supplements, and medical devices. Sinphar has two main business models, including the development of its own products and the licensing of products from other companies. The company has its own manufacturing facility, certified to FDA and GMP (Good Manufacturing Practice) standards, allowing it to produce high-quality drugs. Sinphar offers a wide range of products, including pharmaceuticals, supplements, medical devices, and other health products. It also has a variety of products focusing on the treatment of diseases such as diabetes, cancer, heart disease, and other conditions. The company has several divisions specializing in the development of drugs and medical devices. It also has an extensive research and development department focusing on the development of new drugs and medical devices. Sinphar works closely with various academic institutions and research institutes to stay updated on the latest developments in medicine and utilize the latest technologies. The company has several subsidiaries, including ones in the USA, China, and Singapore. Through these subsidiaries, the company has access to various local markets and can sell its products worldwide. Sinphar has received several awards and recognition for its work in recent years. In 2019, the company was awarded by the Taiwanese Ministry of Education for its exceptional performance in the development of medical devices and pharmaceutical products. Overall, Sinphar Pharmaceutical Co Ltd is a leading player in the pharmaceutical industry with a long history of developing high-quality drugs and medical devices. It specializes in the production of generics and branded drugs and has several divisions specializing in the development of drugs and medical devices. With its subsidiaries and research and development department, the company is well positioned to continue growing and evolving in the future. Sinphar Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Sinphar Pharmaceutical Co's P/S Ratio

Sinphar Pharmaceutical Co's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Sinphar Pharmaceutical Co's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Sinphar Pharmaceutical Co's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Sinphar Pharmaceutical Co’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Sinphar Pharmaceutical Co stock

What is the price-to-earnings ratio of Sinphar Pharmaceutical Co?

The price-earnings ratio of Sinphar Pharmaceutical Co is currently 1.79.

How has the price-earnings ratio of Sinphar Pharmaceutical Co changed compared to last year?

The price-to-earnings ratio of Sinphar Pharmaceutical Co has increased by 16.99% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Sinphar Pharmaceutical Co high compared to other companies?

Yes, the price-to-earnings ratio of Sinphar Pharmaceutical Co is high compared to other companies.

How does an increase in the price-earnings ratio of Sinphar Pharmaceutical Co affect the company?

An increase in the price-earnings ratio of Sinphar Pharmaceutical Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Sinphar Pharmaceutical Co affect the company?

A decrease in the price-earnings ratio of Sinphar Pharmaceutical Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Sinphar Pharmaceutical Co?

Some factors that influence the price-earnings ratio of Sinphar Pharmaceutical Co are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Sinphar Pharmaceutical Co pay?

Over the past 12 months, Sinphar Pharmaceutical Co paid a dividend of 1 TWD . This corresponds to a dividend yield of about 3.04 %. For the coming 12 months, Sinphar Pharmaceutical Co is expected to pay a dividend of 1 TWD.

What is the dividend yield of Sinphar Pharmaceutical Co?

The current dividend yield of Sinphar Pharmaceutical Co is 3.04 %.

When does Sinphar Pharmaceutical Co pay dividends?

Sinphar Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of September, August, August, October.

How secure is the dividend of Sinphar Pharmaceutical Co?

Sinphar Pharmaceutical Co paid dividends every year for the past 20 years.

What is the dividend of Sinphar Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 1 TWD are expected. This corresponds to a dividend yield of 3.04 %.

In which sector is Sinphar Pharmaceutical Co located?

Sinphar Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinphar Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinphar Pharmaceutical Co from 10/8/2024 amounting to 1 TWD, you needed to have the stock in your portfolio before the ex-date on 9/4/2024.

When did Sinphar Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 10/8/2024.

What was the dividend of Sinphar Pharmaceutical Co in the year 2023?

In the year 2023, Sinphar Pharmaceutical Co distributed 0.2 TWD as dividends.

In which currency does Sinphar Pharmaceutical Co pay out the dividend?

The dividends of Sinphar Pharmaceutical Co are distributed in TWD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sinphar Pharmaceutical Co

Our stock analysis for Sinphar Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sinphar Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.